Edgewise Therapeutics Inc Earnings

The next earnings date for Edgewise Therapeutics Inc is November 6, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Edgewise Therapeutics Inc Earnings

Report DateEstimated Earnings Per Share
11/06/2025$-0.44

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Edgewise Therapeutics Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
08/07/2025---$-0.3419.05%
05/07/2025Before Market$-0.43-2.11%
02/20/2025Before Market$-0.420.52%
11/07/2024Before Market$-0.362.70%
08/08/2024Before Market$-0.340.00%
05/09/2024Before Market$-0.3315.38%
02/22/2024Before Market$-0.47-9.30%
11/09/2023Before Market$-0.41-2.50%
08/10/2023Before Market$-0.3415.00%
05/11/2023Before Market$-0.360.00%
02/23/2023Before Market$-0.318.82%
11/03/2022Before Market$-0.345.56%
08/04/2022Before Market$-0.320.00%
05/11/2022Before Market$-0.30-7.14%
02/24/2022Before Market$-0.26-4.00%
11/10/2021Before Market$-0.26-18.18%
08/09/2021Before Market$-0.21-16.67%
05/13/2021After Market$-4.37-2,631.25%
03/26/2021After Market$0---

More About Edgewise Therapeutics Inc

Website
https://edgewisetx.com
Country
USA
Full Time Employees
117

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

“Edgewise Therapeutics Inc Earnings” Can Refer to the Edgewise Therapeutics Inc Earnings Date

Some people say “Edgewise Therapeutics Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Edgewise Therapeutics Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Edgewise Therapeutics Inc Stock on the Earnings Date

If you own Edgewise Therapeutics Inc stock (EWTX) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Edgewise Therapeutics Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Edgewise Therapeutics Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Edgewise Therapeutics Inc Earnings

You can contact us any time if you would like to ask questions about Edgewise Therapeutics Inc earnings or anything else related to the stock market.